REMEGEN (09995): Huang Guobin appointed as independent non-executive director.
Rongchang Biology (09995) announced that Mr. Huang Guobin was appointed as an independent director of the second board of directors at the extraordinary general meeting.
REMEGEN (09995) announced that Mr. Huang Guobin has been appointed as an independent non-executive director of the second board of directors at the temporary shareholders' meeting. Mr. Huang's appointment is effective immediately after the temporary shareholders' meeting and will continue until the end of the second term of the board of directors. Mr. Huang has also been appointed as the chairman of the nomination committee and a member of the strategic committee, effective from his appointment as an independent non-executive director at the temporary shareholders' meeting until the end of the second term of the board of directors.
After the temporary shareholders' meeting, Dr. Ma Lan will no longer serve as an independent non-executive director, chairman of the nomination committee, and member of the strategic committee.
Related Articles

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

Guosen: RWA welcomes the era of strict supervision.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

Guosen: RWA welcomes the era of strict supervision.

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


